SAN DIEGO, Aug. 16, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PT217 for the treatment of neuroendocrine carcinoma (NEC). PT217 is a first-in-class bispecific antibody targeting […]
PT217 is Phanes’ first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche’s anti-PD-L1 monoclonal antibody The clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the treatment of small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinomas (EP-NECs) PT217 was recently granted Fast Track designation by the […]
SAN DIEGO, April 8, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following […]
SAN DIEGO, March 20, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma. PT886 was also granted […]
SAN DIEGO, Jan. 29, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Patent and Trademark Office has granted the registration of trademarks for its proprietary technology platforms PACbody® (Reg. No. 7,080,972), SPECpair® (Reg. No. 7,279,821) and ATACCbody® (Reg. No. 7,075,638). The three […]
PT886 is Phanes’ first-in-class bispecific antibody targeting claudin 18.2 and CD47; KEYTRUDA® (pembrolizumab) is Merck’s anti-PD-1 The clinical trial collaboration will focus on evaluating PT886 in combination with KEYTRUDA® for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas PT886 is also being studied for the treatment of pancreatic cancer SAN DIEGO, Oct. 16, 2023 /PRNewswire/ — […]
SAN DIEGO, Sept. 14, 2023 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company’s Clinical Advisory Board (CAB). “We are excited to have Professor […]
PT217 is a first-in-class bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47) and is Phanes’ third program in the clinic SAN DIEGO, Sept. 7, 2023 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been […]
Distinguished, world renowned experts appointed to strengthen the development of Phanes’ three clinical programs in oncology SAN DIEGO, Sept. 5, 2023 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has formed a Clinical Advisory Board (CAB) to enhance the development of […]
SAN DIEGO, May 30, 2023 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has appointed Rita Laeufle, MD, PhD, as Chief Medical Officer, effective June 1, 2023. Dr. Laeufle has more than 18 years of experience in clinical development in oncology and […]
